Biocept Inc
OTC:BIOCQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Biocept Inc
OTC:BIOCQ
|
US |
|
Proteomics International Laboratories Ltd
ASX:PIQ
|
AU |
Biocept Inc
Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company is headquartered in San Diego, California and currently employs 174 full-time employees. The company went IPO on 2014-02-05. The firm focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood, and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name of CNSide. In addition to CNSide, its current blood-based testing includes its Target Selector technologies, which enables detection of specific gene mutations, such as EGFR, KRAS or BRAF, in cell-free ctDNA from blood samples, as well as specific protein and gene alterations, such as HER2 amplification, in circulating tumor cells (CTCs) isolated from blood. Its multi-modality combination of a cell capture and analysis method used with a cell-free tumor DNA approach provides both high-sensitivity and specificity and is applicable to a range of diagnostic applications in patients with metastatic carcinoma. The company provides blood-based liquid biopsy technology.
Biocept, Inc. is an oncology laboratory service company, which focuses on the development and marketing of novel laboratory products in the detection of rare cells to include circulating tumor cells. The company is headquartered in San Diego, California and currently employs 174 full-time employees. The company went IPO on 2014-02-05. The firm focuses on developing and commercializing clinical diagnostic laboratory assays designed to identify tumor cells and cell-free tumor deoxyribonucleic acid (DNA) from blood, and cerebrospinal fluid (CSF). Its product is branded and trademarked under the name of CNSide. In addition to CNSide, its current blood-based testing includes its Target Selector technologies, which enables detection of specific gene mutations, such as EGFR, KRAS or BRAF, in cell-free ctDNA from blood samples, as well as specific protein and gene alterations, such as HER2 amplification, in circulating tumor cells (CTCs) isolated from blood. Its multi-modality combination of a cell capture and analysis method used with a cell-free tumor DNA approach provides both high-sensitivity and specificity and is applicable to a range of diagnostic applications in patients with metastatic carcinoma. The company provides blood-based liquid biopsy technology.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
